Toukan Labs has successfully rolled out its OpenEyes platform across the Centre for Eye Research Australia (CERA), promising to significantly enhance the efficiency of

The first international results of repeated low-level red-light therapy (RLRL) for myopia have recently been announced by Eyerising International, with the conclusion of the

Syfovre (pegcetacoplan) is now available via private prescription and can be ordered through Australian pharmaceutical distributor CH2.

Opthea has announced it has discontinued its COAST and ShORe trials, for neovascular age-related macular degeneration (nAMD), after the failure of both studies.